Characterization of T Follicular Helper Cells and T Follicular Regulatory Cells in HIV-infected and Sero-negative Individuals

Marta Gori^*
*Correspondence: Marta Gori, Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy, Email:

Introduction

The immune system is a highly orchestrated network of cells and signaling molecules designed to protect the body from infections and foreign invaders. Central to the adaptive immune response are T cells, which play a critical role in recognizing and responding to pathogens. The virus specifically targets CD4+ T cells, including those in the Tfh subset, and disrupts their normal function, leading to a compromised immune response to pathogens and vaccines. Understanding the dysregulation of these immune subsets in HIV infection can provide insights into the mechanisms behind immune exhaustion, the loss of protective immunity, and the failure to control viral replication. This regulation is primarily mediated by T follicular regulatory cells, a subset of CD4+ T cells that function to suppress the activity of Tfh cells and regulate the germinal center response. These inhibitory signals help maintain immune homeostasis by preventing excessive B cell activation, which could lead to autoimmunity or tissue damage. Tfr cells play a critical role in limiting GC reactions and promoting the resolution of immune responses once the infection has been cleared or the vaccine has elicited a sufficient immune response. This article will focus on the characterization of Tfh and Tfr cells in both HIV-infected and seronegative individuals. We will explore their roles in the immune system, their alterations in HIV infection, and their implications for immunity and therapeutic interventions [1-3].

Description

T follicular helper cells are a subset of CD4+ T cells that primarily reside in the Germinal Centers (GC) of secondary lymphoid organs, such as lymph nodes and spleen. They are critical for supporting B cell activation, differentiation, and antibody production. Their main function is to provide essential signals through cytokines and co-stimulatory molecules to promote the activation and survival of B cells in the GC, leading to the production of high-affinity antibodies. The differentiation of Tfh cells is influenced by several key transcription factors, including Bcl-6, which is considered the master regulator of Tfh cell development. Bcl-6 suppresses the expression of other transcription factors associated with other Th cell subsets, such as Th1, Th2, and Th17 cells. Tfh cells also express high levels of CXCR5, a chemokine receptor that guides their migration into the follicles of lymph nodes, where they interact with antigen-activated B cells. Additionally, Tfh cells can also secrete IL-21, a cytokine crucial for B cell differentiation, class-switching, and plasma cell formation. The functional capacity of Tfh cells is essential for effective immune responses, particularly in the context of viral infections and vaccination. For instance, in response to pathogens such as HIV, Tfh cells are involved in the production of antibodies that neutralize the virus and prevent further spread within the body. While Tfh cells are pivotal in activating B cells and driving antibody responses, their activity needs to be carefully controlled to prevent excessive or autoreactive immune responses. The balance between Tfh and Tfr cells is crucial for maintaining both the effectiveness and the safety of the humoral immune response. Dysregulation of this balance can lead to various pathologies, including chronic infections, autoimmune diseases, and immunodeficiency [4,5].

Conclusion

In HIV-infected individuals, the immune system is profoundly affected by the virus, which directly targets and destroys CD4+ T cells, including Tfh cells. These cells are crucial for the production of neutralizing antibodies, and their dysfunction in the context of HIV infection impairs the body’s ability to mount an effective immune response. HIV infection leads to a decrease in the number and function of Tfh cells, which contributes to the failure of humoral immunity. This is particularly evident in the inability to generate robust antibody responses to opportunistic infections or vaccines in many individuals living with HIV, even with effective antiretroviral therapy.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Hall, Deborah A., Alberto R. Ramos, Jeffrey Marc Gelfand and Aleksand er Videnovic, et al. "The state of clinical research in neurology." Neurology 90 (2018): e1347-e1354.

Google Scholar, Crossref, Indexed at

2. Meador, Kimford J. "Decline of clinical research in academic medical centers." Neurology 85 (2015): 1171-1176.

Google Scholar, Crossref, Indexed at

3. Chetlen, Alison L., Andrew J. Degnan, Mark Guelfguat and Brent Griffith, et al. "Radiology research funding: current state and future opportunities." Acad Radiol 25 (2018): 26-39.

Google Scholar, Crossref, Indexed at 

4. Kearney, Anna, Nicola L. Harman, Anna Rosala-Hallas and Claire Beecher, et al. "Development of an online resource for recruitment research in clinical trials to organise and map current literature." Clinical Trials 15 (2018): 533-542.

Google Scholar, Crossref, Indexed at

5. Seufferlein, Thomas and Guido Adler. "Klinische forschung in deutschland am Beispiel der onkologie." Oncol Res Treat 33 (2010): 1-5.

Google Scholar, Crossref, Indexed at